Preclinical efficacy of the PKCβ inhibitor MS-553 in BTKi resistant CLL
Jennifer Woyach • 7 Oct 2023
Phase I/II study of MS-553, a selective PKC-ß Inhibitor, in patients with CLL and SLL
Jennifer Woyach • 12 Dec 2022
Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.